c="Osteogenesis imperfecta" 1:0 1:1||t="problem"||cui="C0029434"||tot="Osteogenesis Imperfecta"||ns="-1000"
c="glycine" 1:7 1:7||t="medication"||cui="C0017890"||tot="Glycine"||ns="-1000"
c="osteogenesis imperfecta (OI" 2:7 2:9||t="problem"||cui="C0029434"||tot="Osteogenesis Imperfecta"||ns="-1000"
c="OI type I" 2:57 2:59||t="problem"||cui="C0023931"||tot="Lobstein's Disease"||ns="-1000"
c="which glycine" 2:68 2:69||t="medication"||cui="C0017890"||tot="Glycine"||ns="-1000"
c="OI type III" 2:84 2:86||t="problem"||cui="C0268362"||tot="Osteogenesis imperfecta type III"||ns="-1000"
c="which glycine" 2:95 2:96||t="medication"||cui="C0017890"||tot="Glycine"||ns="-1000"
c="OI type II" 2:113 2:115||t="problem"||cui="C0268358"||tot="Osteogenesis imperfecta, perinatal lethal"||ns="-1000"
c="glycine" 2:174 2:174||t="medication"||cui="C0017890"||tot="Glycine"||ns="-1000"
